TScan Therapeutics, Inc. stock is up 66.41% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 14.29% of the previous 9 December’s closed higher than November.
TScan Therapeutics, Inc. develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.